Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib and Toripalimab in Recurrent Biliary Tract Cancer
NCT05056116Phase 2Unknown
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of surufatinib in biliary tract cancer (BTC), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Objective Response Rate at 24 months. Status: unknown.
02
Drugs
surufatinib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT05056116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05056116.